A clinical study on the safety of immune-cell therapy combined with standard therapy for high-grade glioma
Phase 1
- Conditions
- glioma
- Registration Number
- JPRN-UMIN000032147
- Lead Sponsor
- Juntendo University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia 2)Have a history of a serious drug allergy 3)Have a positive result of HIV or HTLV-1 antibody test 4)Have a serious cardiac disorder 5)Have an active autoimmune disorder 6)Have a cancer other than glioma 7)Have an infectious disorder that is difficult to control 8)Be a female who is pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method The quality of life for patients